Mohan Nallicheri Viswanathan, MD
Cardiac Electrophysiology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Viswanathan’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A80904 · Current
Licensed to practise in California · since 2002 · expires 2028-04-30 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$213,732
Medicare paid this office $213,732 for 1,242 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 42 | $34,418 | $819 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 126 | $21,603 | $154 |
| Long return visit (40+ min) | 99 | $18,641 | $171 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 44 | $16,245 | $254 |
| New patient visit (60+ min) | 69 | $13,671 | $198 |
See all 24 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 42 | $34,418 | $819 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 126 | $21,603 | $154 |
| Long return visit (40+ min) | 99 | $18,641 | $171 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 44 | $16,245 | $254 |
| New patient visit (60+ min) | 69 | $13,671 | $198 |
| Long return visit (40+ min) | 96 | $13,045 | $129 |
| New patient visit (60+ min) | 83 | $12,920 | $156 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 21 | $9,172 | $437 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 12 | $8,442 | $704 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 51 | $7,837 | $106 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 23 | $7,138 | $255 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 677 | $5,453 | $7 |
| Hospital discharge day management, more than 30 minutes | 38 | $4,080 | $105 |
| Removal and replacement of dual lead permanent pacemaker | 12 | $3,718 | $310 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 113 | $2,233 | $19 |
| Programming of dual lead pacemaker system | 49 | $1,849 | $32 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 52 | $1,445 | $24 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 27 | $1,290 | $31 |
| Programming of heart rhythm stimulation after drug infusion | 20 | $1,211 | $61 |
| Programming of dual lead implantable defibrillator system | 20 | $1,048 | $50 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 13 | $820 | $63 |
| Programming of multiple lead implantable defibrillator system | 15 | $781 | $52 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 48 | $504 | $10 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 16 | $226 | $14 |
Procedures Medicare counted
| Pacemaker insertion or repair | 49 | More than 89% of doctors who do this |
Who their Medicare patients are
1,242 Original Medicare patients in 2024. Average age 75 · Under 65 9% · 85 and older 17% · Women 48% · Also on Medicaid 27% · Health risk score 2.23. Sicker patients than 9 in 10 peers; the typical clinical cardiac electrophysiology clinician is at 1.8.
Conditions among them: High blood pressure 75% · Atrial fibrillation 60% · Coronary heart disease 50% · Heart failure 47% · Chronic kidney disease 42% · Diabetes 37% · Depression 25% · Cancer 21% · COPD 20% · Stroke 17% · Dementia 16%.
The office billed $1,657,092, Medicare allowed $271,380 and paid $213,732; for 2,110 services of 59 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,242 | 2,110 | 75 | 2.23 | $1,657,092 | $213,732 |
| 2023 | 1,254 | 2,291 | 75 | 2.14 | $1,604,878 | $213,882 |
| 2022 | 830 | 1,704 | 75 | 1.81 | $1,253,678 | $177,230 |
| 2021 | 1,122 | 2,431 | 74 | 1.93 | $1,465,051 | $225,660 |
| 2020 | 811 | 1,813 | 75 | 1.98 | $1,114,157 | $172,118 |
| 2019 | 714 | 1,543 | 74 | 2.03 | $650,495 | $140,498 |
| 2018 | 536 | 1,530 | 73 | 1.81 | $896,607 | $178,288 |
| 2017 | 519 | 1,464 | 73 | 1.88 | $814,319 | $173,055 |
| 2016 | 658 | 1,801 | 74 | 1.94 | $1,053,400 | $215,556 |
| 2015 | 726 | 1,583 | 73 | 2.06 | $806,251 | $165,793 |
| 2014 | 789 | 1,362 | 74 | 1.88 | $476,795 | $100,648 |
| 2013 | 540 | 1,094 | 70 | 2.02 | $378,091 | $101,763 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 26 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 37 | $30,060 | $812 |
| Long return visit (40+ min) | 172 | $25,931 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 92 | $15,993 | $160 |
| New patient visit (60+ min) | 89 | $14,402 | $162 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 18 | $13,133 | $730 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 29 | $12,814 | $442 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 34 | $12,593 | $268 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of lower chamber of heart causing ventricular tachycardia (rapid heart rate) or ventricular ectopy (irregular heartbeat) | 12 | $10,388 | $866 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 20 | $8,038 | $268 |
| New patient visit (60+ min) | 36 | $7,555 | $210 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 43 | $6,099 | $109 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 672 | $5,767 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 102 | $4,745 | $27 |
| Long return visit (40+ min) | 23 | $4,184 | $174 |
| Hospital discharge day management, more than 30 minutes | 38 | $4,070 | $107 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 58 | $3,540 | $34 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 121 | $2,943 | $24 |
| Programming of dual lead pacemaker system | 71 | $2,881 | $34 |
| Programming of heart rhythm stimulation after drug infusion | 23 | $1,842 | $80 |
| Programming of multiple lead implantable defibrillator system | 27 | $1,819 | $57 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 19 | $1,320 | $69 |
| Programming of dual lead implantable defibrillator system | 19 | $1,030 | $52 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 15 | $865 | $24 |
| Programming of multiple lead pacemaker system | 11 | $505 | $39 |
| Telehealth originating site facility fee | 14 | $314 | $22 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 30 | $142 | $5 |
2022: 21 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 28 | $27,386 | $978 |
| Long return visit (40+ min) | 162 | $21,856 | $126 |
| New patient visit (60+ min) | 99 | $16,120 | $163 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 16 | $11,563 | $723 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 24 | $10,957 | $457 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 52 | $10,079 | $180 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 244 | $6,986 | $24 |
| New patient visit (60+ min) | 31 | $6,552 | $211 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 154 | $6,070 | $26 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 18 | $5,717 | $272 |
| Long return visit (40+ min) | 22 | $4,232 | $169 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 71 | $3,834 | $32 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $3,448 | $93 |
| Programming of dual lead pacemaker system | 76 | $3,254 | $34 |
| Programming of multiple lead implantable defibrillator system | 22 | $1,382 | $53 |
| Programming of dual lead implantable defibrillator system | 20 | $1,218 | $51 |
| Programming of heart rhythm stimulation after drug infusion | 11 | $1,122 | $102 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 133 | $1,105 | $7 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 18 | $651 | $20 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 25 | $564 | $23 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 15 | $76 | $5 |
2021: 26 services
| Long return visit (40+ min) | 187 | $27,458 | $130 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 24 | $23,990 | $1,000 |
| New patient visit (60+ min) | 105 | $18,257 | $174 |
| Insertion of implantable defibrillator system | 16 | $13,455 | $841 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 65 | $13,138 | $185 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 16 | $11,722 | $733 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 24 | $10,690 | $445 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 40 | $10,245 | $256 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 156 | $8,137 | $26 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 17 | $7,959 | $379 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 17 | $7,094 | $417 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 229 | $6,336 | $24 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 85 | $6,324 | $33 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $5,360 | $94 |
| Programming of dual lead pacemaker system | 97 | $5,217 | $35 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 38 | $4,513 | $116 |
| New patient visit (60+ min) | 18 | $3,907 | $217 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 419 | $3,732 | $8 |
| Long return visit (40+ min) | 13 | $2,306 | $165 |
| Programming of multiple lead implantable defibrillator system | 36 | $2,301 | $58 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 16 | $1,789 | $105 |
| Hospital discharge day management, more than 30 minutes | 15 | $1,457 | $97 |
| Programming of dual lead implantable defibrillator system | 22 | $1,403 | $52 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 21 | $1,109 | $24 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 14 | $323 | $23 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $236 | $20 |
2020: 26 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 21 | $21,294 | $1,014 |
| Long return visit (40+ min) | 172 | $19,861 | $100 |
| New patient visit (60+ min) | 95 | $14,032 | $148 |
| Insertion of implantable defibrillator system | 12 | $10,223 | $852 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 21 | $9,849 | $469 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | 11 | $9,257 | $771 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 32 | $8,800 | $267 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,345 | $188 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 134 | $6,937 | $29 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 79 | $5,548 | $36 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 205 | $5,083 | $21 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 11 | $5,020 | $386 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 12 | $4,598 | $383 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 31 | $4,186 | $97 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 28 | $4,009 | $138 |
| Programming of dual lead pacemaker system | 81 | $3,887 | $34 |
| Programming of multiple lead implantable defibrillator system | 29 | $1,997 | $57 |
| Long return visit (40+ min) | 17 | $1,827 | $107 |
| Telephone medical discussion with physician, 21-30 minutes | 25 | $1,761 | $70 |
| Programming of heart rhythm stimulation after drug infusion | 12 | $1,758 | $147 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 186 | $1,659 | $8 |
| Programming of dual lead implantable defibrillator system | 21 | $1,488 | $55 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,426 | $102 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 17 | $967 | $25 |
| Programming of multiple lead pacemaker system | 11 | $582 | $42 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 16 | $181 | $11 |
2019: 20 services
| Long return visit (40+ min) | 194 | $20,450 | $99 |
| New patient visit (60+ min) | 113 | $16,805 | $149 |
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 11 | $10,873 | $988 |
| Insertion of implantable defibrillator system | 11 | $8,985 | $817 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 18 | $8,292 | $461 |
| Programming of dual lead pacemaker system | 132 | $7,425 | $34 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,690 | $184 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 67 | $4,864 | $38 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 11 | $4,116 | $374 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 16 | $3,976 | $248 |
| Programming of multiple lead implantable defibrillator system | 38 | $3,387 | $56 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 81 | $3,081 | $25 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $2,641 | $94 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 19 | $2,536 | $133 |
| Programming of dual lead implantable defibrillator system | 32 | $2,413 | $54 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 77 | $1,962 | $25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 203 | $1,750 | $8 |
| Programming of heart rhythm stimulation after drug infusion | 12 | $1,692 | $141 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 12 | $1,244 | $104 |
| Programming of multiple lead pacemaker system | 13 | $804 | $38 |
2018: 23 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 21 | $21,431 | $974 |
| Long return visit (40+ min) | 186 | $20,235 | $93 |
| New patient visit (60+ min) | 100 | $14,112 | $141 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 30 | $13,679 | $456 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 57 | $10,733 | $182 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 30 | $8,849 | $285 |
| Programming of dual lead pacemaker system | 132 | $8,145 | $34 |
| Long return visit (40+ min) | 38 | $5,672 | $118 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 14 | $5,530 | $369 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 39 | $5,336 | $94 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 12 | $4,801 | $369 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 51 | $4,484 | $47 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 28 | $3,821 | $132 |
| Programming of dual lead implantable defibrillator system | 43 | $2,843 | $50 |
| Programming of multiple lead implantable defibrillator system | 37 | $2,830 | $54 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 71 | $2,678 | $25 |
| New patient visit (60+ min) | 14 | $2,331 | $166 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,679 | $99 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 12 | $1,128 | $94 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 34 | $907 | $25 |
| Programming of multiple lead pacemaker system | 12 | $866 | $38 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 47 | $401 | $7 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 23 | $265 | $11 |
2017: 24 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 28 | $27,289 | $975 |
| New patient visit (60+ min) | 121 | $17,269 | $143 |
| Long return visit (40+ min) | 151 | $15,819 | $94 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 30 | $10,318 | $344 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 17 | $7,809 | $459 |
| Long return visit (40+ min) | 46 | $7,669 | $114 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 20 | $7,364 | $368 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,889 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 35 | $6,637 | $93 |
| Programming of dual lead pacemaker system | 114 | $6,605 | $34 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 12 | $4,881 | $407 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 49 | $4,878 | $59 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 12 | $4,432 | $369 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 32 | $4,222 | $132 |
| New patient visit (60+ min) | 23 | $3,866 | $168 |
| Programming of multiple lead implantable defibrillator system | 35 | $3,219 | $56 |
| Programming of dual lead implantable defibrillator system | 33 | $2,522 | $53 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 56 | $2,241 | $28 |
| Programming of heart rhythm stimulation after drug infusion | 12 | $1,635 | $136 |
| Return visit (30+ min) | 24 | $1,619 | $67 |
| Review and interpretation of external ekg recording for more than 48 hours up to 21 days | 33 | $808 | $24 |
| Programming of single lead pacemaker system | 15 | $621 | $30 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 57 | $564 | $6 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 20 | $218 | $11 |
2016: 27 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 34 | $32,148 | $946 |
| Long return visit (40+ min) | 143 | $16,578 | $93 |
| New patient visit (60+ min) | 109 | $15,801 | $145 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 37 | $12,684 | $343 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 27 | $12,472 | $462 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $12,037 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $11,897 | $180 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 27 | $9,860 | $365 |
| Insertion of implantable defibrillator system | 12 | $9,766 | $814 |
| Programming of dual lead pacemaker system | 118 | $7,256 | $34 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 39 | $5,206 | $130 |
| New patient visit (60+ min) | 30 | $4,794 | $160 |
| Long return visit (40+ min) | 35 | $4,756 | $99 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 12 | $4,385 | $365 |
| Removal and replacement of multiple lead defibrillator | 11 | $3,906 | $355 |
| Programming of multiple lead implantable defibrillator system | 38 | $3,506 | $55 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 35 | $3,367 | $59 |
| Programming of heart rhythm stimulation after drug infusion | 20 | $2,754 | $138 |
| Hospital discharge day management, more than 30 minutes | 27 | $2,624 | $97 |
| Programming of dual lead implantable defibrillator system | 25 | $1,953 | $51 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 183 | $1,935 | $8 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 48 | $1,923 | $30 |
| Return visit (30+ min) | 20 | $1,331 | $67 |
| Insertion of catheters for recording and pacing of left upper heart chamber rhythm and induction of abnormal rhythm | 12 | $1,215 | $101 |
| Programming of single lead pacemaker system | 21 | $933 | $29 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 47 | $444 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 11 | $266 | $19 |
2015: 26 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 21 | $20,340 | $969 |
| New patient visit (60+ min) | 126 | $18,673 | $148 |
| Long return visit (40+ min) | 105 | $14,686 | $96 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 27 | $12,477 | $462 |
| Insertion of implantable defibrillator system | 15 | $11,576 | $772 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 25 | $8,475 | $339 |
| Destruction of tissue of upper heart chamber through tube to treat abnormal heart rhythm | 17 | $6,145 | $361 |
| New patient visit (60+ min) | 36 | $6,021 | $167 |
| Insertion of catheters and destruction of tissue to treat abnormal heart rhythm | 16 | $5,789 | $362 |
| Programming of dual lead pacemaker system | 95 | $5,188 | $34 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $5,014 | $179 |
| Insertion of left lower heart electrode for pacemaker or defibrillator | 11 | $4,382 | $398 |
| Removal and replacement of multiple lead defibrillator | 11 | $4,016 | $365 |
| Programming of multiple lead implantable defibrillator system | 37 | $3,997 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $3,316 | $92 |
| Long return visit (40+ min) | 23 | $3,220 | $111 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 354 | $3,075 | $7 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 23 | $2,993 | $130 |
| Return visit (30+ min) | 34 | $2,580 | $64 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | 20 | $1,573 | $58 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,160 | $97 |
| Programming of dual lead implantable defibrillator system | 15 | $1,053 | $50 |
| Programming of single lead pacemaker system | 20 | $723 | $28 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 16 | $666 | $29 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 44 | $418 | $7 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system | 16 | $385 | $18 |
2014: 15 services
| New patient visit (60+ min) | 67 | $9,963 | $149 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 17 | $7,830 | $461 |
| Long return visit (40+ min) | 63 | $5,956 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $4,621 | $92 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 494 | $4,474 | $8 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 24 | $4,458 | $178 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 11 | $3,695 | $336 |
| Programming of dual lead pacemaker system | 77 | $3,508 | $33 |
| Programming of multiple lead implantable defibrillator system | 39 | $2,705 | $55 |
| Programming of dual lead implantable defibrillator system | 32 | $2,200 | $51 |
| New patient visit (60+ min) | 13 | $2,175 | $167 |
| Return visit (30+ min) | 34 | $2,034 | $58 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,139 | $63 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 21 | $491 | $23 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 11 | $76 | $7 |
2013: 22 services
| Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | 12 | $10,702 | $892 |
| Insertion of pacemaker and upper and lower heart chamber electrode | 20 | $8,621 | $431 |
| Insertion of implantable defibrillator system | 11 | $8,229 | $748 |
| New patient visit (60+ min) | 57 | $7,115 | $125 |
| Insertion of tube for 3d mapping of electrical impulses to heart muscle | 19 | $5,922 | $312 |
| Return visit (30+ min) | 89 | $5,346 | $57 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $3,449 | $164 |
| Long return visit (40+ min) | 34 | $3,160 | $83 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 308 | $2,709 | $7 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 30 | $2,324 | $58 |
| Programming of heart rhythm stimulation after drug infusion | 17 | $2,292 | $127 |
| Ultrasound evaluation of heart blood vessel with review by radiologist | 14 | $1,610 | $115 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 13 | $1,452 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,085 | $83 |
| Programming of dual lead pacemaker system | 27 | $920 | $30 |
| Programming of dual lead implantable defibrillator system | 19 | $876 | $46 |
| Programming of multiple lead implantable defibrillator system | 16 | $849 | $50 |
| Evaluation of single, dual, or multiple lead implantable defibrillator system | 19 | $769 | $37 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 11 | $505 | $32 |
| Programming of single lead implantable defibrillator system | 13 | $385 | $30 |
| Electrocardiogram (ecg) up to 30 days continuous with review and report by health care professional | 19 | $375 | $20 |
| Electrocardiogram (ecg) 2-day continuous with review by health care professional | 13 | $322 | $21 |
Medicaid work
$5,504 in 2024
Medicaid paid $5,504 for 579 billed services this clinician did in 2024, up to 115 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 567 | $5,324 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 12 | $180 |
| 2024 | 579 | 2 | 115 | $5,504 |
| 2023 | 668 | 2 | 97 | $5,362 |
| 2022 | 255 | 2 | 85 | $2,853 |
| 2021 | 535 | 4 | 70 | $6,168 |
| 2020 | 183 | 3 | 39 | $2,043 |
| 2019 | 118 | 1 | 43 | $1,153 |
See the largest Medicaid services in earlier years
2023
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 653 | $5,235 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 15 | $127 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 198 | $1,709 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 57 | $1,144 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 424 | $4,412 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 79 | $976 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead implantable defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 12 | $478 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 20 | $302 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 158 | $1,568 |
| Long return visit (40+ min) | 12 | $349 |
| Interrogation device evaluation(s) (remote), up to 90 days; single, dual, or multiple lead pacemaker system, or leadless pacemaker system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional | 13 | $126 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 118 | $1,153 |
Drugs they prescribed that Part D paid
$303,942
Pharmacies billed $303,942 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 733) in 2024. At or below the middle of the specialty; the typical clinical cardiac electrophysiology clinician is at 0%.
499 generic and 234 brand-name prescriptions · $303,942 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 179 | $224,610 | $1,255 |
| Xarelto | 44 | $54,062 | $1,229 |
| Dofetilide | 32 | $9,737 | $304 |
| Metoprolol | 156 | $2,725 | $17 |
| Mexiletine | 31 | $2,341 | $76 |
See all 12 drugs
| Eliquis | 179 | $224,610 | $1,255 |
| Xarelto | 44 | $54,062 | $1,229 |
| Dofetilide | 32 | $9,737 | $304 |
| Metoprolol | 156 | $2,725 | $17 |
| Mexiletine | 31 | $2,341 | $76 |
| Flecainide Acetate | 34 | $1,690 | $50 |
| Diltiazem 24hr Er (Cd) | 34 | $1,075 | $32 |
| Amiodarone | 38 | $1,013 | $27 |
| Sotalol | 38 | $791 | $21 |
| Pantoprazole | 35 | $238 | $7 |
| Metoprolol | 21 | $186 | $9 |
| Carvedilol | 17 | $60 | $4 |
Year by year
| 2024 | 733 | 201 | 0% (0) | 32% | $303,942 |
| 2023 | 770 | 211 | 0% (0) | 30% | $350,922 |
| 2022 | 722 | 204 | 0% (0) | 30% | $365,180 |
| 2021 | 710 | 186 | 0% (0) | 29% | $297,677 |
| 2020 | 847 | 184 | 0% (0) | 36% | $337,321 |
| 2019 | 768 | 169 | 0% (0) | 35% | $242,655 |
| 2018 | 840 | 171 | 0% (0) | 31% | $154,962 |
| 2017 | 716 | 149 | 0% (0) | 32% | $101,750 |
| 2016 | 472 | 105 | 0% (0) | 29% | $53,944 |
| 2015 | 309 | 88 | 0% (0) | 21% | $32,163 |
| 2014 | 137 | 47 | None | None | $5,105 |
| 2013 | 136 | 43 | None | None | $5,126 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 13 drugs
| Eliquis | 165 | $223,272 | $1,353 |
| Xarelto | 50 | $81,396 | $1,628 |
| Dofetilide | 48 | $16,267 | $339 |
| Mexiletine | 26 | $4,691 | $180 |
| Metoprolol | 138 | $3,489 | $25 |
| Flecainide Acetate | 45 | $2,471 | $55 |
| Amiodarone | 60 | $2,277 | $38 |
| Diltiazem 24hr Er (Cd) | 39 | $1,446 | $37 |
| Sotalol | 26 | $690 | $27 |
| Carvedilol | 16 | $316 | $20 |
| Pantoprazole | 37 | $297 | $8 |
| Metoprolol | 23 | $242 | $11 |
| Diltiazem | 24 | $91 | $4 |
2022: 16 drugs
| Eliquis | 150 | $200,710 | $1,338 |
| Xarelto | 41 | $64,070 | $1,563 |
| Dofetilide | 70 | $37,100 | $530 |
| Pradaxa | 18 | $20,106 | $1,117 |
| Enoxaparin | 13 | $13,034 | $1,003 |
| Mexiletine | 28 | $3,546 | $127 |
| Metoprolol | 98 | $2,516 | $26 |
| Flecainide Acetate | 41 | $2,472 | $60 |
| Diltiazem 24hr Er (Cd) | 34 | $1,373 | $40 |
| Amiodarone | 43 | $1,283 | $30 |
| Carvedilol | 20 | $370 | $18 |
| Sotalol | 21 | $322 | $15 |
| Metoprolol | 30 | $308 | $10 |
| Atenolol | 22 | $289 | $13 |
| Diltiazem | 18 | $273 | $15 |
| Pantoprazole | 26 | $175 | $7 |
2021: 16 drugs
| Eliquis | 111 | $145,217 | $1,308 |
| Xarelto | 53 | $69,721 | $1,315 |
| Dofetilide | 73 | $26,801 | $367 |
| Multaq | 13 | $19,404 | $1,493 |
| Pradaxa | 17 | $16,763 | $986 |
| Mexiletine | 25 | $4,032 | $161 |
| Metoprolol | 105 | $3,106 | $30 |
| Flecainide Acetate | 27 | $2,757 | $102 |
| Diltiazem 24hr Er (Cd) | 39 | $2,110 | $54 |
| Amiodarone | 39 | $870 | $22 |
| Carvedilol | 30 | $614 | $20 |
| Sotalol | 22 | $465 | $21 |
| Metoprolol | 34 | $271 | $8 |
| Lisinopril | 12 | $170 | $14 |
| Pantoprazole | 26 | $168 | $6 |
| Atenolol | 27 | $121 | $4 |
2020: 19 drugs
| Eliquis | 138 | $155,793 | $1,129 |
| Xarelto | 94 | $91,639 | $975 |
| Dofetilide | 99 | $27,181 | $275 |
| Multaq | 24 | $21,840 | $910 |
| Pradaxa | 19 | $18,157 | $956 |
| Enoxaparin | 15 | $4,961 | $331 |
| Mexiletine | 20 | $4,134 | $207 |
| Flecainide Acetate | 39 | $3,062 | $79 |
| Metoprolol | 99 | $3,003 | $30 |
| Amiodarone | 69 | $1,484 | $22 |
| Diltiazem 24hr Er (Cd) | 22 | $1,428 | $65 |
| Propafenone | 11 | $677 | $62 |
| Carvedilol | 39 | $456 | $12 |
| Sucralfate | 14 | $441 | $32 |
| Sotalol | 19 | $392 | $21 |
| Metoprolol | 26 | $257 | $10 |
| Pantoprazole | 29 | $227 | $8 |
| Spironolactone | 11 | $198 | $18 |
| Atenolol | 19 | $104 | $5 |
2019: 15 drugs
| Eliquis | 119 | $88,178 | $741 |
| Xarelto | 78 | $61,655 | $790 |
| Dofetilide | 69 | $32,873 | $476 |
| Multaq | 19 | $18,709 | $985 |
| Pradaxa | 27 | $18,250 | $676 |
| Enoxaparin | 13 | $5,196 | $400 |
| Metoprolol | 125 | $4,081 | $33 |
| Flecainide Acetate | 43 | $2,691 | $63 |
| Amiodarone | 67 | $1,477 | $22 |
| Diltiazem | 23 | $1,067 | $46 |
| Diltiazem 24hr Er (Cd) | 13 | $641 | $49 |
| Sucralfate | 18 | $610 | $34 |
| Carvedilol | 32 | $454 | $14 |
| Metoprolol | 22 | $137 | $6 |
| Pantoprazole | 12 | $99 | $8 |
2018: 18 drugs
| Xarelto | 99 | $51,942 | $525 |
| Eliquis | 81 | $35,864 | $443 |
| Dofetilide | 49 | $22,246 | $454 |
| Pradaxa | 28 | $16,224 | $579 |
| Multaq | 12 | $8,963 | $747 |
| Metoprolol | 124 | $3,317 | $27 |
| Flecainide Acetate | 62 | $2,864 | $46 |
| Amiodarone | 62 | $2,654 | $43 |
| Enoxaparin | 13 | $844 | $65 |
| Sucralfate | 19 | $621 | $33 |
| Diltiazem 24hr Er (Cd) | 17 | $611 | $36 |
| Diltiazem | 22 | $600 | $27 |
| Carvedilol | 41 | $374 | $9 |
| Cartia Xt | 26 | $334 | $13 |
| Pantoprazole | 24 | $184 | $8 |
| Metoprolol | 36 | $182 | $5 |
| Warfarin | 14 | $97 | $7 |
| Cephalexin | 11 | $52 | $5 |
2017: 17 drugs
| Xarelto | 75 | $33,939 | $453 |
| Eliquis | 67 | $27,124 | $405 |
| Dofetilide | 33 | $11,607 | $352 |
| Pradaxa | 11 | $5,385 | $490 |
| Amiodarone | 86 | $3,987 | $46 |
| Flecainide Acetate | 44 | $2,545 | $58 |
| Enoxaparin | 31 | $2,295 | $74 |
| Metoprolol | 90 | $1,962 | $22 |
| Diltiazem | 31 | $1,765 | $57 |
| Digoxin | 12 | $512 | $43 |
| Diltiazem 24hr Er | 14 | $485 | $35 |
| Sotalol | 13 | $344 | $26 |
| Cartia Xt | 24 | $264 | $11 |
| Bisoprolol | 11 | $234 | $21 |
| Carvedilol | 26 | $198 | $8 |
| Pantoprazole | 25 | $190 | $8 |
| Metoprolol | 37 | $176 | $5 |
2016: 13 drugs
| Xarelto | 48 | $21,651 | $451 |
| Eliquis | 27 | $9,651 | $357 |
| Enoxaparin | 16 | $2,990 | $187 |
| Flecainide Acetate | 28 | $1,568 | $56 |
| Metoprolol | 50 | $894 | $18 |
| Amiodarone | 39 | $759 | $19 |
| Sotalol | 15 | $705 | $47 |
| Diltiazem | 13 | $643 | $49 |
| Metoprolol | 40 | $192 | $5 |
| Warfarin | 16 | $184 | $11 |
| Levothyroxine | 12 | $166 | $14 |
| Pantoprazole | 20 | $141 | $7 |
| Carvedilol | 11 | $87 | $8 |
2015: 10 drugs
| Xarelto | 24 | $12,058 | $502 |
| Eliquis | 12 | $7,631 | $636 |
| Flecainide Acetate | 11 | $797 | $72 |
| Amiodarone | 32 | $351 | $11 |
| Metoprolol | 16 | $306 | $19 |
| Warfarin | 28 | $299 | $11 |
| Carvedilol | 21 | $118 | $6 |
| Metoprolol | 29 | $114 | $4 |
| Cephalexin | 17 | $94 | $6 |
| Lisinopril | 14 | $41 | $3 |
2014: 3 drugs
| Amiodarone | 30 | $1,279 | $43 |
| Metoprolol | 20 | $724 | $36 |
| Flecainide Acetate | 12 | $284 | $24 |
2013: 4 drugs
| Metoprolol | 19 | $1,007 | $53 |
| Flecainide Acetate | 17 | $474 | $28 |
| Amiodarone | 18 | $299 | $17 |
| Carvedilol | 13 | $149 | $11 |
Money from drug and device companies
$4,117 in 2025
| 2025 | 5 | 31 | None | $4,117 |
| 2024 | 4 | 21 | None | $3,857 |
| 2023 | 4 | 7 | None | $496 |
| 2022 | 2 | 5 | None | $499 |
| 2021 | 2 | 3 | $409 | $473 |
| 2020 | 3 | 3 | $210 | $243 |
| 2019 | 7 | 27 | $5,057 | $15,473 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | Farapulse | $2,044 | 9 payments
|
| Abbott Laboratories | Aveir | $1,596 | 14 payments
|
| Biosense Webster | Carto 3 | $400 | 6 payments
|
| Medtronic | Affera Mapping System | $63 | 1 payment
|
| Cordis US | Mynx Control Venous | $14 | 1 payment
|
See all 31 published payments
| Biosense Webster | Meals · 2025-12-18 | Nuvision Ice Catheter | $98 |
| Boston Scientific | Meals · 2025-12-18 | Rhythmia Mapping System | $66 |
| Medtronic | Meals · 2025-12-18 | Affera Mapping System | $63 |
| Biosense Webster | Meals · 2025-11-11 | Carto 3 | $16 |
| Cordis US | Meals · 2025-10-29 | Mynx Control Venous | $14 |
| Abbott Laboratories | Meals · 2025-10-07 | Aveir | $75 |
| Abbott Laboratories | Meals · 2025-10-07 | Aveir | $32 |
| Abbott Laboratories | Meals · 2025-10-07 | Aveir | $33 |
| Abbott Laboratories | Meals · 2025-10-07 | Aveir | $53 |
| Abbott Laboratories | Travel · 2025-10-07 | Aveir | $203 |
| Abbott Laboratories | Travel · 2025-10-07 | Aveir | $133 |
| Boston Scientific | Meals · 2025-10-04 | Farapulse | $455 |
| Boston Scientific | Meals · 2025-10-03 | Farapulse | $550 |
| Boston Scientific | Travel · 2025-10-03 | Farapulse | $277 |
| Boston Scientific | Meals · 2025-10-02 | Farapulse | $10 |
| Boston Scientific | Travel · 2025-10-02 | Farapulse | $388 |
| Abbott Laboratories | Travel · 2025-09-26 | Aveir | $33 |
| Abbott Laboratories | Travel · 2025-09-26 | Aveir | $176 |
| Abbott Laboratories | Travel · 2025-09-26 | Aveir | $745 |
| Abbott Laboratories | Travel · 2025-09-26 | Aveir | $9 |
| Biosense Webster | Meals · 2025-06-27 | Carto 3 | $147 |
| Abbott Laboratories | Meals · 2025-06-02 | Aveir | $53 |
| Biosense Webster | Meals · 2025-05-14 | Carto 3 | $12 |
| Biosense Webster | Meals · 2025-04-24 | Carto 3 | $110 |
| Boston Scientific | Meals · 2025-04-24 | General - Therapies | $75 |
| Abbott Laboratories | Meals · 2025-03-25 | None | $17 |
| Abbott Laboratories | Meals · 2025-03-20 | Ensite | $17 |
| Boston Scientific | Travel · 2025-02-20 | Farapulse | $172 |
| Boston Scientific | Meals · 2025-02-20 | Farapulse | $52 |
| Abbott Laboratories | Meals · 2025-02-17 | Ensite | $19 |
| Biosense Webster | Meals · 2025-02-12 | Carto 3 | $17 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,857
| Abbott Laboratories | Aveir | $2,083 | 15 payments
|
| Boston Scientific | None | $1,489 | 3 payments
|
| Medtronic | Micra | $149 | 2 payments
|
| Biosense Webster | Carto 3 | $136 | 1 payment
|
2023: $496
| Abbott Laboratories | Ensite Precision | $243 | 3 payments
|
| Biosense Webster | Carto 3 | $182 | 2 payments
|
| Siemens Medical Solutions USA | None | $56 | 1 payment
|
| Cardiva Medical | Cardiva Vascade Mvp Vvcs 6-12f | $14 | 1 payment
|
2022: $499
| Biosense Webster | Carto 3 | $258 | 2 payments
|
| Abbott Laboratories | Ensite Precision | $241 | 3 payments
|
2021: $473
| ZOLL Medical | None | $409 | 1 payment
|
| Biosense Webster | Carto 3 | $64 | 2 payments
|
2020: $243
| Genzyme | Multaq | $160 | 1 payment
|
| Bard Peripheral Vascular | Bd Introsyte | $50 | 1 payment
|
| Biosense Webster | Carto 3 System | $33 | 1 payment
|
2019: $15,473
| Philips Electronics North America | Igt Systems Und | $9,459 | 1 payment
|
| iRhythm Technologies | Zio Patch | $4,057 | 3 payments
|
| Medtronic Vascular | Micra | $550 | 10 payments
|
| Biotronik | Siello | $500 | 2 payments
|
| Cardiva Medical | Vascular Closure Device | $500 | 1 payment
|
| Abbott Laboratories | Advisor Catheter | $212 | 5 payments
|
| Boston Scientific | General Ep | $195 | 5 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Medtronic Vascular, Inc. · Adaptresponse · 2019 | Their institution | $66,804 |
| Medtronic Vascular, Inc. · Adaptresponse · 2020 | Their institution | $56,354 |
| Medtronic, Inc. · Adaptresponse · 2022 | Their institution | $43,320 |
| BOSTON SCIENTIFIC CORPORATION · Preempt Hf · 2020 | Their institution | $34,283 |
| Medtronic, Inc. · Adaptresponse · 2021 | Their institution | $26,149 |
| Biosense Webster, Inc. · Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bwi Ire Ablation System · 2023 | Their institution | $19,142 |
| Abbott Laboratories · A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457q Left Ventricular Lead, An Investigational Device Exemption (Ide) Study · 2019 | Their institution | $8,482 |
| Boston Scientific Corporation · Preempt Hf · 2021 | Their institution | $7,420 |
| Medtronic, Inc. · Adaptresponse · 2023 | Their institution | $5,838 |
| Biosense Webster, Inc. · Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the Bwi Ire Ablation System · 2024 | Their institution | $4,157 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1689898397
- Licence
- CA A 80904California A80904: Current · expires 2028-04-30
- Trained
- University of California, San Francisco School of Medicine, 1999
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0001X (207RC0001X); Internal medicine (207R00000X); Cardiology (207RC0000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-04-12
- NPI last updated
- 2024-04-26
- NPI record certified
- 2024-04-26
This is when the NPI record was last certified, not a medical board exam.